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Genome-wide association studies (GWAS) have identiﬁed more than 170 breast cancer
susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-
breast tissues, speciﬁcally adipose tissue and immune cells from blood and spleen. Using
expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously
unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen
receptor (ER)-negative breast cancer, several with a known immune function. We determine
the directional effect of gene expression on disease risk measured based on single and
multiple eQTL. In addition, using a gene-based test of association that considers eQTL from
multiple tissues, we identify seven (and four) regions with variants associated with overall
(and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further
investigation of the function of the implicated genes in breast and immune cells may provide
insights into the etiology of breast cancer.
https://doi.org/10.1038/s41467-018-08053-5 OPEN
Correspondence and requests for materials should be addressed to M.A.F. (email: Manuel.Ferreira@qimr.edu.au). These authors contributed equally:
Jonathan Beesley, Georgia Chenevix-rench. #A full list of authors and their afﬁliations appears at the end of the paper.
NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Breast cancer is the most commonly diagnosed malignancyand most frequent cause of cancer-related mortality inwomen1. Genome-wide association studies (GWAS) have
detected more than 170 genomic loci harboring common variants
associated with breast cancer risk, including 20 primarily asso-
ciated with risk of ER-negative disease2,3. Together, these com-
mon variants account for 18% of the two-fold familial relative risk
of breast cancer2.
To translate GWAS ﬁndings into an improved understanding of
the biology underlying disease risk, it is essential to ﬁrst identify the
target genes of risk-associated variants. This is not straightforward
because most risk variants lie in non-coding regions, particularly
enhancers, many of which do not target the nearest gene4. To help
with this task, we recently developed a pipeline that identiﬁes
likely target genes of breast cancer risk variants based on breast
tissue-speciﬁc genomic data, such as promoter–enhancer chro-
matin interactions and expression quantitative trait loci (eQTL)2.
Using this approach, called INQUISIT, we identiﬁed 689 genes as
potential targets of the breast cancer risk variants. However, it is
likely that at least some breast cancer risk variants modulate gene
expression in tissues other than breast, which were not considered
by INQUISIT; for example, breast cancer risk variants are enriched
in histone marks measured in adipose tissue2. On the other hand,
the immune system also plays a role in the elimination of cancer
cells5 so it is possible that some breast cancer risk variants inﬂu-
ence the expression of genes that function in the immune system.
The ﬁrst aim of this study was to identify additional likely
target genes of the breast cancer risk variants identiﬁed by the
Breast Cancer Association Consortium2,3 using information on
eQTL in multiple relevant tissue types: adipose, breast, immune
cells, spleen, and whole-blood. The second aim was to identify
previously unreported risk loci for breast cancer by formally
integrating eQTL information across tissues with results from
the GWAS2,3 using EUGENE, a recently described gene-based
test of association6,7, that is conceptually similar to other
transcriptome-wide association study (TWAS) approaches, such
as PrediXcan8. Gene-based analyses would be expected to
identify previously unreported risk loci if, for example, multiple
independent eQTL for a given gene are individually associated
with disease risk, but not at the genome-wide signiﬁcance level
used for single-variant analyses.
Results
Predicted target genes of overall breast cancer risk variants.
Using approximate joint association analysis implemented in
GCTA9 (see Methods), we ﬁrst identiﬁed 212 variants that were
independently associated (i.e. with GCTA-COJO joint analysis
P < 5 × 10−8) with breast cancer in a GWAS dataset of 122,977
cases and 105,974 controls2 (Supplementary Data 1). Of note, 20
of these variants reached genome-wide signiﬁcance in the joint,
but not in the original single-variant, association analysis; that is,
they represent secondary signals that were masked by the asso-
ciation with other nearby risk variants, as described previously9.
We extracted association summary statistics from 117 published
eQTL datasets identiﬁed in ﬁve broad tissue types: adipose, breast,
individual immune cell types, spleen and whole-blood (Supple-
mentary Data 2). For each gene and for a given eQTL dataset, we
identiﬁed cis eQTL (within 1Mb of gene boundaries) in low
linkage disequilibrium (LD; r2 < 0.05) with each other, and with
an association with gene expression signiﬁcant at a conservative
signiﬁcance threshold of 8.9 × 10−10. We refer to these as “sentinel
eQTL”. The mean number of sentinel eQTL per gene ranged
from 1.0 to 2.9 across the 117 eQTL datasets considered, which
varied considerably in sample size and number of genes tested
(Supplementary Data 2).
When we intersected the list of variants from the joint
association analysis and the list of sentinel eQTL from published
datasets, we identiﬁed 46 sentinel risk variants that were in high
LD (r2 > 0.8) with one or more sentinel eQTL, implicating 88
individual genes at 46 loci as likely targets of breast cancer risk
variants (Supplementary Data 3 and 4). Twenty-ﬁve risk variants
had a single predicted target gene, 10 had two, and 11 had three
or more (Supplementary Data 5).
Of the 88 genes, 75 (85%) were identiﬁed based on eQTL
from whole-blood, 10 (11%) from immune cells (PEX14, RNF115,
TNNT3, EFEMP2, SDHA, AP4B1, BCL2L15, BTN3A2,
HIST1H2BL, SYNE1), and three (4%) exclusively from adipose
tissue (ZNF703, HAPLN4, TM6SF2) (Supplementary Data 4).
Only four sentinel risk variants were in LD with a sentinel eQTL
in breast tissue (for ATG10, PIDD1, RCCD1, and APOBEC3B);
all were also eQTL in whole-blood and immune cells. However,
it is noteworthy that an additional 29 sentinel eQTL listed in
Supplementary Data 3 had a modest, yet signiﬁcant association
with the expression of the respective target gene in breast tissue
(GTEx V7, n= 251), suggesting that larger eQTL datasets of this
tissue will be informative to identify the target genes of sentinel
risk variants.
A total of 62 genes were included in the list of 925 targets
predicted in the original GWAS using INQUISIT2, while 26 genes
represent previously unreported predictions (Supplementary
Data 5). Regional association plots for these 26 genes are
presented in Supplementary Fig. 1, with three examples shown in
Fig. 1.
Directional effect of gene expression on breast cancer risk. For
the 88 genes identiﬁed as likely targets of breast cancer risk
variants, we studied the directional effect of genetically-
determined gene expression on disease risk, based on the senti-
nel eQTL that was in LD with the sentinel risk variant. For each
gene, we ﬁrst determined whether the eQTL allele that was
associated with reduced breast cancer risk was associated with
higher or lower target gene expression. Of the 77 genes for which
this information could be obtained (detailed in Supplementary
Data 4), the protective allele was associated with lower expression
for 43 genes (e.g. GATAD2A, FAM175A, KCNN4, and CTB-
161K23.1) and higher expression for 28 genes (e.g. RCCD1,
ATG10, ELL, and TLR1) (summarized in Table 1 and Supple-
mentary Data 6). For the remaining six genes (ADCY3, AMFR,
APOBEC3B, CCDC127, HSPA4, and MRPS18C), conﬂicting
directional effects were observed across different tissues, and
so the interpretation of results is not straightforward.
Directional effect based on information from multiple eQTL.
In the previous analysis, the directional effect of gene expression
on disease risk was assessed based on a single eQTL at a time.
However, the expression of most genes is associated with
multiple independent eQTL, which may not have the same
directional effect on disease risk. To address this limitation,
we assessed if results from the single QTL analyses above were
recapitulated by considering information from multiple eQTL
using S-PrediXcan10. We applied this approach to the same
GWAS results2 and used transcriptome prediction models
from whole-blood, generated based on data from the Depression
Genes and Network study (n= 92211) and GTEx (n= 369). We
used SNP prediction models for gene expression in whole-blood
because most genes (75 of 88) were identiﬁed as likely targets
based on eQTL information from this tissue.
Results from this analysis are presented in Supplementary
Data 7. The predicted directional effect of gene expression
on disease risk was available in both the single eQTL and
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S-PrediXcan analyses for 48 of the 88 likely target genes. For 42
of those 48 genes (88%) the two predictions matched, supporting
a consistent directional effect across multiple eQTL of the
same gene. The inconsistent results observed for the remaining
six genes were likely caused by technical biases (possible
explanations in Supplementary Data 7). Similar ﬁndings were
obtained when considering whole-blood transcriptome
prediction models based on data from the GTEx consortium
(Supplementary Data 7). Overall, these results indicate very good
agreement between the directional effect of gene expression on
disease risk obtained using information from individual or
multiple eQTL.
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Target gene predictions supported by functional data. The 88
genes identiﬁed represent target predictions that should be
experimentally validated, as outlined previously12. To help
prioritize genes for functional follow-up, we identiﬁed a subset for
which publicly available functional data supported the presence of
either (i) chromatin interactions between an enhancer and the
gene promoter4,13–15; or (ii) an association between variation in
enhancer epigenetic marks and variation in gene expression
levels16–19. We only considered enhancers that overlapped a
sentinel risk variant (or a proxy with r2 > 0.80) and restricted our
analysis to blood cells (Supplementary Data 8), given that most
target genes were identiﬁed based on eQTL data from whole-
blood. We found that 25 (28%) of the 88 target gene predictions
were supported by functional data (Supplementary Data 9).
Previously unreported risk loci for breast cancer. The second
major goal of this study was to identify previously unreported
risk loci for breast cancer using gene-based association analyses.
We ﬁrst used approximate conditional analysis implemented
in GCTA9 to adjust the GWAS results2 (Fig. 2a) for the effect-
s of the 212 variants that had a signiﬁcant independent associa-
tion with overall breast cancer. As expected, in the resulting
adjusted GWAS no single variant had a genome-wide signiﬁcant
association (i.e. all had a GCTA-COJO conditional association
P > 5 × 10−8; Fig. 2b). We then applied the EUGENE gene-based
approach6,7 to the adjusted GWAS results, considering in a single
association analysis cis eQTL identiﬁed in ﬁve broad tissue types:
adipose, breast, immune cells, spleen, and whole-blood (Supple-
mentary Data 10). That is, we did not perform a separate gene-
based analysis for each tissue, but rather a single analysis that
considers all eQTL reported across the ﬁve tissues.
Of the 19,478 genes tested (full results provided as Supple-
mentary Material), 11 had a signiﬁcant gene-based association
after correcting for multiple testing (EUGENE P < 0.05/19,478=
2.5 × 10−6; Table 2; Fig. 2c). The speciﬁc eQTL included in the
gene-based test for each of these 11 genes, which were located in
six loci >1Mb apart, are listed in Supplementary Data 10.
Regional association plots for the 11 genes are presented in
Supplementary Fig. 2, with three examples shown in Fig. 3.
Except for the MAN2C1 locus20, these loci have not previously
been identiﬁed by GWAS and thus represent putative breast
cancer susceptibility loci.
For most (9 of 11) genes identiﬁed, the association P-value
obtained with the gene- based test was more signiﬁcant than the
P-value obtained with the individual eQTL most associated with
disease risk, indicating that multiple sentinel eQTL for the same
gene were associated with disease risk (range 2–6 associated
eQTL per gene; Table 2). For example, the EUGENE gene-based
P-value for GSTM2 was 6.6 × 10−8, while the best individual
eQTL showed more moderate association with breast cancer risk
(GCTA-COJO conditional association P= 4.1 × 10−5; ﬁve of the
14 sentinel eQTL tested for this gene were nominally associated
with disease risk (Supplementary Data 11).
We also studied the predicted directional effect of gene
expression on disease risk, as described above for target genes
of known breast cancer risk variants. When we considered
information from all eQTL associated with disease risk for each of
the 11 genes (Supplementary Data 11), we found that decreased
disease risk was consistently associated with decreased gene
expression for three genes and increased expression for ﬁve genes
(Table 3 and Supplementary Data 12). For the remaining three
genes, inconsistent directional effects were observed across
different eQTL.
Lastly, we used EUGENE to determine if any of the 88 target
genes of sentinel risk variants identiﬁed based on individual
eQTL also had a signiﬁcant gene-based association in the
adjusted GWAS results. This would indicate that information
from additional breast cancer risk variants (i.e. in low LD with
the sentinel risk variants) supported the original target gene
prediction, which could be used to prioritize genes for functional
follow-up. We found that 11 of the 88 target genes had a
nominally signiﬁcant gene-based association in the adjusted
GWAS results (EUGENE P < 0.05; Supplementary Data 13), with
one remaining signiﬁcant after correcting for multiple testing:
CBX6 (EUGENE P= 0.0002).
Fig. 1 Examples of previously unreported target gene predictions at known breast cancer risk loci. Variants are represented by points colored according to
the LD with the sentinel risk variant (red: ≥0.8, orange: 0.6–0.8, green: 0.4–0.6, light blue: 0.2–0.4, and dark blue: <0.2). Sentinel risk variants (triangles)
were identiﬁed based on joint association analysis9. Figure shows on the y-axis the evidence for breast cancer association (−log10 of the P-value in the
original published GWAS results2, obtained in that study using an inverse-variance meta-analysis), and on the x-axis chromosomal position. Gene
structures from GENCODE v19 gene annotations are shown and the predicted target genes shown in red. a The sentinel risk variant at this locus (rs875311)
was in LD with sentinel eQTL for CFL1 (in whole blood) and for EFEMP2 (in CD8+ T cells only). b The sentinel risk variant (rs11049425, target gene:
CCDC91) represents a secondary association signal in this region. c The sentinel risk variant at this locus (rs8105994) is in LD with sentinel eQTL for two
previously unreported target gene predictions (AC010335.1 and LRRC25) and four previously predicted targets (CTD-3137H5.1, ELL, PGPEP1 and SSBP4;
(Supplementary Data 5). Regional association plots for the remaining target gene predictions for overall breast cancer (Supplementary Data 3) are
provided in Supplementary Figure 1
Table 1 Directional effect of genetically determined gene expression on disease risk for predicted target genes of breast cancer
sentinel risk variants
Directional effect Predicted target genes of breast cancer sentinel risk variants
Decreased expression associated with
decreased risk
AC007283.5, AHRR, AP006621.5, AP006621.6, APOBEC3B-AS1, ARRDC3, ASCC2, BCL2L15, BTN2A1,
CCDC170, CCDC91, CDCA7L, CEND1, CES1, COX11, CTB-161K23.1, CTD-2116F7.1, CYP51A1, DDA1, DFFA,
EFEMP2, ENPP7, FAM175A, GATAD2A, HAPLN4, HCG11, HIST1H4L, KCNN4, LRRC25, LRRD1, OGFOD1, PIDD1,
PPIL3, PTPN22, RPS23, SIRT5, SMG9, TGFBR2, TM6SF2, TMEM184B, TNS1, ZBTB38, ZNF703
Increased expression associated with
decreased risk
AC010335.1, AKAP9, APOBEC3A, ATF7IP, ATG10, ATP6AP1L, BTN2A3P, CBX6, CENPO, CFL1, COQ5, CTD-
3137H5.1, DCLRE1B, DNAJC27, ELL, ESR1, HLF, L3MBTL3, NUDT17, PGPEP1, RCCD1, RHBDD3, RNF115, RP11-
486M23.2, SIVA1, SYNE1, TEFM, TLR1
Ambiguous ADCY3, AMFR, APOBEC3B, CCDC127, HSPA4, MRPS18C
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Estrogen receptor (ER)-negative breast cancer. We applied the
same analyses described above to results from the Milne et al.
GWAS of ER-negative breast cancer, which included data on
21,468 cases and 100,594 controls, combined with 18,908 BRCA1
mutation carriers (9414 with breast cancer)3.
Of the 54 sentinel risk variants identiﬁed through approximate
joint association analysis (Supplementary Data 14), 19 were in
LD (r2 > 0.8) with a sentinel eQTL (Supplementary Data 15),
implicating 24 genes as likely targets of risk-associated variants
for ER-negative breast cancer (Supplementary Data 16). Of these,
13 were also identiﬁed as likely targets of variants associated with
overall breast cancer risk, while the remaining 11 genes were
speciﬁc to ER-negative risk variants: ATM, CCNE1, CUL5,
MCHR1, MDM4, NPAT, OCEL1, PIK3C2B, RALB, RP5-
855D21.3, and WDR43.
Seventeen genes were not highlighted as candidate target
genes in the Milne et al. GWAS3 (Supplementary Data 16 and
Supplementary Data 17), mostly (15 genes) because they are
predicted targets of risk variants identiﬁed in previous GWAS,
which were not considered by Milne et al.3. The two exceptions
were RP5-855D21.3 and CUL5, identiﬁed in our study based
on eQTL from adipose tissue and whole-blood, respectively.
Regional association plots for the 17 genes that represent
previously unreported predictions are presented in Supplemen-
tary Fig. 3, with three examples shown in Fig. 4.
The disease protective allele was associated with lower gene
expression for seven genes and higher gene expression for 11
genes (summary in Table 4 and Supplementary Data 18; detailed
information in Supplementary Data 15); for the remaining six
genes, directional effect was either not available (ATM, CASP8,
OCEL1, PEX14 and WDR43) or inconsistent across tissues
(ADCY3).
Of the 24 target gene predictions, 18 were supported by the
presence of enhancer– promoter chromatin interactions or an
association between enhancer epigenetic marks and gene
expression (Supplementary Data 19).
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When we applied EUGENE to the ER-negative GWAS results
obtained after conditioning on the 54 sentinel risk variants,
we identiﬁed four genes in four loci with a signiﬁcant gene-
based association (EUGENE P < 2.5 × 10−6; Table 5, Supplemen-
tary Data 20 and Supplementary Fig. 4). Of these, we found that
lower disease risk was consistently associated with lower
expression for two genes (VPS52, GTF2IRD2B) and higher
expression for one gene (INHBB). For the fourth gene (TNFSF10),
directional effect was inconsistent across sentinel eQTL (detail
and summary in Supplementary Tables 21 and 22, respectively).
Other genes that could be prioritized for functional follow-up
include four (of the 24) target genes of sentinel risk variants that
had a nominally signiﬁcant gene-based association in the adjusted
GWAS results (EUGENE P < 0.05; Supplementary Data 23):
RALB, CCDC170, NPAT, and CASP8.
Known role of the identiﬁed genes in cancer biology. We used
OncoScore, a text-mining tool that ranks genes according to their
association with cancer based on available biomedical literature21,
to assess the extent to which each of the breast cancer genes we
identiﬁed were already known to have a role in cancer. Of the 112
genes we identiﬁed across the overall and ER-negative analyses
that could be scored by OncoScore, 48 scored below the recom-
mended OncoScore cut-off threshold (21.09) for novelty,
including 25 with an OncoScore of 0, indicating no prior evidence
for a role in cancer biology (Tables 2 and 5; Supplementary
Tables 3 and 16). For the remaining 64 genes there is an extensive
literature on their role in cancer, and breast cancer in particular.
Discussion
To predict candidate target genes at breast cancer risk loci, we
identiﬁed sentinel eQTL in multiple tissues that were in high LD
(r2 > 0.8) with sentinel risk variants from our recent GWAS2.
Using this approach, we implicated 88 genes as likely targets of
the overall breast cancer risk variants. Because eQTL are wide-
spread, it is possible that some target gene predictions are false-
positives due to coincidental overlap between sentinel eQTL and
sentinel risk SNPs. At the LD threshold used, statistical methods
developed recently to formally test for co-localization between
eQTL and risk SNPs are of limited use, due to a high false-
positive rate22. The 88 genes identiﬁed therefore represent target
predictions that must be validated by functional studies. Of these
88, 26 genes had not been predicted as targets using a different
approach that considered breast-speciﬁc functional annotations
and eQTL data2, and so were considered previously unreported
candidate target genes.
Of the 26 previously unreported target predictions, all but one
were identiﬁed from eQTL analyses in blood, spleen, or immune
cells. They include several genes with a known role in immunity,
including: HLF, the expression of which is associated with the
extent of lymphocytic inﬁltration after neo-adjuvant chemother-
apy23; PTPN22, a shared autoimmunity gene24, which encodes
a protein tyrosine phosphatase that negatively regulates pre-
sentation of immune complex-derived antigens25; and RHBDD3,
a negative regulator of TLR3-triggered natural killer cell activa-
tion26, and critical regulator of dendritic cell activation27. In
addition, we identiﬁed IRF1, which encodes a tumor suppressor
and transcriptional regulator serving as an activator of genes
involved in both innate and acquired immune response28,29, as
a previously unreported breast cancer risk locus. These results
suggest that at least some of the previously unreported predicted
target genes play a role in cancer cell elimination or inﬂamma-
tion. However, another possibility is that eQTL detected in well-
powered studies of blood are predictors of eQTL in other less
accessible tissues, including breast and adipose tissue. Consistent
with this possibility, about 50% of the eQTL found to be in LD
with a sentinel risk variant for overall breast cancer (and similarly
for ER-negative breast cancer) were associated with the expres-
sion of the respective target gene in the relatively small GTEx
breast tissue dataset, although not at the conservative threshold
that we used to deﬁne sentinel eQTL. Of note, one previously
unreported target was identiﬁed through eQTL analyses in adi-
pose tissue: ZNF703. ZNF703 is a known oncogene in breast
cancer30, and has been reported to be associated with breast size31
which might suggest a role in adiposity.
Using the same approach, we also identiﬁed 24 genes as likely
targets of 19 ER- negative risk variants, of which 17 were not
proposed as candidate target genes in the original GWAS3. Eleven
of these 22 genes were unique to ER-negative breast cancer,
including for example CUL5, a core component of multiple SCF-
like ECS (Elongin-Cullin 2/5-SOCS-box protein) E3 ubiquitin-
protein ligase complexes which recognize proteins for degrada-
tion and subsequent Class I mediated antigen presentation32.
We also identiﬁed previously unreported breast cancer risk loci
using the recently described EUGENE gene-based association
test6,7, which was developed to aggregate evidence for association
with a disease or trait across multiple eQTL. Unlike other similar
gene-based methods (e.g. S-PrediXcan), EUGENE includes in a
single test information from eQTL identiﬁed in multiple tissues;
Table 2 Risk loci for breast cancer identiﬁed in the EUGENE gene-based analysis but not in previous GWAS
Locus
index
Gene Chr Start N sentinel eQTL Gene-based
P-valuea
Sentinel eQTL with strongest
association in the adjusted GWAS
OncoScore
Tested with P < 0.05 in
adjusted GWASb
Variant P-valueb
1 GSTM2 1 110210644 14 5 6.63E−08 rs621414 4.08E−05 38.97
2 SEMA4A 1 156117157 9 5 1.45E−07 rs887953 2.39E−06 27.04
3 LINC00886 3 156465135 1 1 2.34E−06 rs7641929 2.34E−06 N/A
4 AC034220.3 5 131646978 7 4 5.92E−07 rs11739622 0.000314 N/A
4 IRF1 5 131817301 2 2 4.99E−07 rs2548998 3.44E−05 42.46
5 SIK2 11 111473115 2 2 4.09E−07 rs527078 3.32E−05 39.57
5 PPP2R1B 11 111597632 8 2 2.31E−06 rs680096 2.91E−06 56.52
6 MAN2C1 15 75648133 14 6 1.91E−06 rs8028277 2.16E−06 26.66
6 RP11-817O13.8 15 75660496 4 4 3.83E−08 rs4545784 3.85E−06 N/A
6 SIN3A 15 75661720 4 4 3.83E−08 rs4545784 3.85E−06 42.43
6 IMP3 15 75931426 1 1 2.30E−06 rs4886708 2.30E−06 80.41
aGene-based association P-value obtained when the EUGENE gene-based test was applied to the adjusted GWAS results
bP-value in the Michailidou et al. 2. GWAS, adjusted for (i) the association with the sentinel risk variants identiﬁed in this study using the COJO-COND test; and (ii) the LD-score intercept
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this property is expected to increase power to detect gene asso-
ciations when multiple cell types/tissues contribute to disease
pathophysiology, for two main reasons. First, because tissue-
speciﬁc eQTL are common, and so a multi-tissue analysis is able
to capture the association between all known eQTL and disease
risk in a single test. Second, because in single-tissue analyses,
one needs to appropriately account for testing multiple tissues,
thereby decreasing the signiﬁcance threshold required for
experiment-wide signiﬁcance, which decreases power. When we
applied EUGENE to the overall breast cancer GWAS2, we iden-
tiﬁed 11 associated genes located in six previously unreported
risk loci. For most of these genes, there were multiple sentinel
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eQTL associated with overall breast cancer risk. In the analysis of
ER-negative breast cancer3, EUGENE identiﬁed four associated
genes (INHBB, TNFSF10, VPS52, and GTF2IRD2B) located in
four previously unreported risk loci.
Some of the predicted target genes identiﬁed are well known to
play a role in breast cancer carcinogenesis. For example, the genes
identiﬁed for ER-negative breast cancer included MDM4,
encoding a negative regulator of TP53, which is necessary for
normal breast development33; CCNE1, an important oncogene in
breast cancer34,35; CASP8, encoding a regulator of apoptosis36;
ATM, a known breast cancer susceptibility gene37,38; and the
ER, ESR1, which encodes a critical transcription factor in breast
tissue39. On the other hand, the 11 signiﬁcant gene-based asso-
ciations for overall breast cancer included GSTM2, which is part
of the mu class of glutathione S-transferases that are involved in
increased susceptibility to environmental toxins and carcino-
gens40. Other noteworthy gene-based associations included those
with: IMP3, which contributes to self-renewal and tumor initia-
tion, properties associated with cancer stem cells41; PPP2R1B,
which encodes the beta isoform of subunit A of Protein Phos-
phatase 2A, itself a tumor suppressor involved in modulating
estrogen and androgen signaling in breast cancer42; and
SEMA4A43, recently shown to regulate the migration of cancer
cells as well as dendritic cells44.
Two recent studies reported results from analyses that are
similar in scope to those carried out in our study. First, Hoffman
et al.45 reported that genetically determined expression of six
genes was associated with risk of breast cancer: three when
considering expression in breast tissue (RCCD1, DHODH, and
ANKLE1) and three in whole blood (RCCD1, ACAP1, and
LRRC25). Of note, RCCD1 and LRRC25 were identiﬁed as likely
targets of known breast cancer risk variants in our analysis. We
also found some support for an association between breast cancer
risk and eQTL for ACAP1 (EUGENE P= 0.003) and ANKLE1
(EUGENE P= 0.01), but not for DHODH (best sentinel eQTL
P= 0.119). Second, we recently applied a different gene-based
approach called S-PrediXCan to results from the overall breast
cancer GWAS2, using gene expression levels predicted from
breast tissue20.
This study reported signiﬁcant associations with 46 genes
(P < 5.82 × 10−6), including 13 located in 10 regions not yet
implicated by GWAS. A major difference between our analyses
is that the latter were based on the original GWAS summary
statistics, without adjusting for the effects of the sentinel risk
variants. This explains why most associated genes in their main
analysis were located near known breast cancer risk variants.
Of the 13 genes located in previously unreported risk loci, eight
were tested in our analysis (which considered eQTL identiﬁed
in multiple tissues, not just from breast as in ref. 20), of which four
had a nominally signiﬁcant (P < 0.05) gene-based association:
MAN2C1 (P= 1.9 × 10−6), SPATA18 (P= 0.004), B3GNT1
(P= 0.012), and CTD-2323K18.1 (P= 0.021). These results show
that at least four of the associations reported by Wu et al.20, which
were based on information from breast eQTL only, are repro-
ducible when a different gene-based approach is applied to
the same GWAS results. Conversely, we identiﬁed a signiﬁcant
association with 13 genes not reported by Wu et al.20, all with a
gene-based association driven by eQTL identiﬁed in non-breast
tissues, mostly in immune cells and/or whole-blood. For 78 of the
114 genes that we implicate in breast cancer risk, either through
target gene prediction or gene-based analyses, we were able to
determine the directional effect of the breast cancer protective
alleles on gene expression. In some cases, this was consistent with
their known function. For example, ZNF703 is a well-known
oncogene in breast cancer30 and decreased expression was asso-
ciated with decreased risk. Similarly, oncogenic activity has been
reported for PIK2C2B46, for which we found that decreased
expression is associated with decreased risk. Another gene for
which decreased expression was associated with decreased risk was
PTPN22 which is known to negatively regulate antigen presenta-
tion47 and therefore might suppress immunoelimination. By
contrast, CCNE148 and APOBEC3A49 have been reported to have
oncogenic roles, but we found that increased expression was
associated with decreased risk. We have previously found the
same counterintuitive relationship between breast cancer risk
alleles and CCND1 expression50. However, the expression patterns
observed in breast tumors may not be relevant to the activity of
these genes in the progenitor cells that give rise to breast tumors.
The directional effect of genetically determined gene expres-
sion on breast cancer risk is important because drugs that mimic
the effect of the protective allele on gene expression might be
expected to attenuate (rather than exacerbate) disease risk. For
example, decreased risk of ER-negative breast cancer was asso-
ciated with decreased expression of KCNN4, suggesting that an
antagonist that targets this potassium channel and has a good
safety proﬁle51 might reduce disease risk. Given these results,
we suggest that KCNN4 should be prioritized for functional and
pre-clinical follow up.
Fig. 3 Examples of signiﬁcant gene-based associations at loci not previously reported in breast cancer GWAS. Variants are represented by points colored
according to the LD with the sentinel risk variant (red: ≥0.8, orange: 0.6–0.8, green: 0.4–0.6, light blue: 0.2–0.4, and dark blue: <0.2). Sentinel eQTL
included in the EUGENE analysis (triangles) were identiﬁed from published eQTL studies of ﬁve different tissue types. Figure shows on the y-axis the
evidence for breast cancer association (−log10 of the P-value in the published GWAS after adjusting for the association with the sentinel risk variants using
the COJO-COND test, and the LD-score intercept), and on the x-axis chromosomal position. The sentinel eQTL most associated with breast cancer risk
is depicted by a black triangle; other sentinel eQTL included in the gene-based test are depicted by red triangles. Gene structures from GENCODE v19
gene annotations are shown and the predicted target genes shown in red. a–c show examples of three previously unreported loci which respectively
implicate PPP2R1B, IMP3 and GSTM2 as candidate breast cancer susceptibility genes. Regional association plots for the remaining eight gene- based
associations are provided in Supplementary Figure 2
Table 3 Directional effect of genetically determined gene expression on disease risk for genes identiﬁed in the gene-based
analysis of the adjusted breast cancer GWAS
Direction of effect Predicted target genes of breast cancer sentinel risk variants
Decreased expression associated with decreased risk IMP3, IRF1, SEMA4A
Increased expression associated with decreased risk LINC00886, MAN2C1, RP11-817O13.8, SIK2, SIN3A
Ambiguous AC034220.3, GSTM2, PPP2R1B
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Fig. 4 Examples of previously unreported target gene predictions at known ER- negative breast cancer risk loci. Variants are represented by points colored
according to the LD with the sentinel risk variant (red: ≥0.8, orange: 0.6–0.8, green: 0.4–0.6, light blue: 0.2–0.4, and dark blue: <0.2). Sentinel risk
variants (triangles) were identiﬁed based on joint association analysis9. Figure shows on the y-axis the evidence for ER-negative breast cancer association
(−log10 of the P-value in the original published GWAS results3, obtained in that study using an inverse-variance meta-analysis), and on the x-axis
chromosomal position. Gene structures from GENCODE v19 gene annotations are shown and the predicted target genes shown in red. The sentinel risk
variants are in LD with sentinel eQTL for MDM4 and PIK3C2B (a), ZNF703 (b), and ATM (c; Supplementary Data 17). Regional association plots for
the remaining 14 previously unreported target gene predictions are provided in Supplementary Figure 3
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In summary, we have used the largest available GWAS of
breast cancer, along with expression data from multiple different
tissues, to identify 26 and 17 previously unreported likely target
genes of known overall and ER-negative breast cancer risk var-
iants, respectively. We also describe signiﬁcant gene-based asso-
ciations at six and four previously unreported risk loci for overall
and ER-negative breast cancer, respectively. Further investigation
into the function of the genes identiﬁed in breast and immune
cells, particularly those which have additional support from
experimental or computational predictions of chromatin looping,
should provide additional insight into the etiology of breast
cancer.
Methods
Predicting target genes of breast cancer risk variants. Recently, Michailidou
et al.2 reported a breast cancer GWAS meta-analysis that combined results from
13 studies: the OncoArray study (61,282 cases and 45,494 controls); the iCOGS
study (46,785 cases and 42,892 controls); and 11 other individual GWAS (with
a combined 14,910 cases and 17,588 controls). That is, a total of 122,977 cases
and 105,974 controls. The ﬁrst aim of our study was to identify likely target genes
of breast cancer risk variants identiﬁed in that GWAS.
First, we identiﬁed variants associated with variation in gene expression (i.e.
eQTL) in published transcriptome studies of ﬁve broad tissue types: adipose, breast,
immune cells isolated from peripheral blood, spleen and whole- blood. We
identiﬁed a total of 35 transcriptome studies reporting results from eQTL analyses
in any one of those ﬁve tissue types (Supplementary Data 2). Some studies included
multiple cell types and/or experimental conditions, resulting in a total of
86 separate eQTL datasets. For each eQTL dataset, we then (i) downloaded the
original publication tables containing results for the eQTL reported; (ii) extracted
the variant identiﬁer, gene name, association P-value and, if available, the effect size
(speciﬁcally, by “effect size” we mean the beta/z-score) and corresponding allele;
(iii) excluded eQTL located >1Mb of the respective gene (i.e. trans eQTL), because
often these are thought to be mediated by cis effects52; (iv) excluded eQTL with
an association P > 8.9 × 10−10, a conservative threshold that corrects for 55,764
transcriptsin Gencode v19, each tested for association with 1000 variants (as
suggested by others53–55); and (v) for each gene, used the --clump procedure in
PLINK to reduce the list of eQTL identiﬁed (which often included many correlated
variants) to a set of ‘sentinel eQTL’, deﬁned as the variants with strongest
association with gene expression and in low LD (r2 < 0.05, linkage disequilibrium
(LD) window of 2 Mb) with each other.
Second, we identiﬁed variants that were independently associated with breast
cancer risk at a P < 5 × 10−8 in the GWAS reported by Michailidou et al. 2, which
included 122,977 cases and 105,974 controls. We refer to these as “sentinel risk
variants” for breast cancer. To identify independent associations, we ﬁrst excluded
from the original GWAS (which tested 12,396,529 variants) variants with: (i) a
sample size < 150,000; (ii) a minor allele frequency < 1%; (iii) not present in, or not
polymorphic (Europeans) in, or with alleles that did not match, data from the 1000
Genomes project (release 20130502_v5a); and (iv) not present in, or with alleles
that did not match, data from the UK Biobank study56. After these exclusions,
results were available for 8,248,946 variants. Next, we identiﬁed sentinel risk
variants using the joint association analysis (--cojo- slct) option of GCTA9, using
imputed data from 5000 Europeans from the UK Biobank study56 to calculate LD
between variants. These individuals were selected based on the sample IDs (lowest
5000) from our approved UK Biobank application 25331.
Third, we identiﬁed genes for which a sentinel eQTL reported in any of the
86 eQTL datasets described above was in high LD (r2 > 0.8) with a breast cancer
sentinel risk variant. That is, we only considered genes for which there was high LD
between a sentinel eQTL and a sentinel risk variant, which reduces the chance
of spurious co-localization.
Directional effect of gene expression on breast cancer risk. Having identiﬁed
a list of genes with expression levels correlated with sentinel risk variants, we
then studied the directional effect of the breast cancer protective allele on gene
expression. For each sentinel eQTL in high LD (r2 > 0.8) with a sentinel risk
variant, we: (i) identiﬁed the allele that was associated with reduced breast cancer
risk, based on results reported by Michailidou et al. 2; and (ii) determined if that
allele was associated with increased or decreased target gene expression in each
of the eQTL datasets that reported that eQTL. For many studies, the directional
effect of eQTL (i.e. effect allele and beta) was not publicly available, and so for those
this analysis could not be performed.
We also assessed whether the directional effect of gene expression on disease
risk predicted by the approach described in the previous paragraph, which
considered one eQTL at a time (a limitation) but many different eQTL datasets
(a strength), would be recapitulated by applying S-PrediXcan10 to the same breast
cancer GWAS2 using transcriptome information from 922 whole-blood samples
studied by Battle et al.11. S-PrediXcan considers information from multiple eQTL
identiﬁed for a given gene in a given tissue (e.g. whole-blood) when determining
the association between genetically determined gene expression levels and disease
risk. Therefore, we reasoned that this approach could be particularly useful for
genes with multiple independent eQTL identiﬁed in the same tissue. The limitation
of this approach is that it ﬁrst requires the generation of gene expression prediction
models based on individual-level variant and transcriptome data, which are not
publicly available for most of the 35 transcriptome studies included in our analysis.
We used gene expression models generated based on the whole-blood dataset of
Battle et al.11 because (i) most likely target genes were identiﬁed in our study based
on eQTL information from whole-blood or immune cells isolated from whole-
blood; and (ii) this was the largest transcriptome dataset we had access to.
Target gene predictions supported by functional data. Sentinels and variants in
high LD (r2 > 0.8 in Europeans of the 1000 Genomes Project, with MAF > 0.01)
were queried against the following sources of publicly available data generated from
blood-derived samples and cell lines. Computational methods linking regulatory
elements with target genes including PreSTIGE17, FANTOM516, IM-PET18,
enhancers and super enhancers from Hnisz et al.19. Experimental chromatin
looping data deﬁned by ChIA-PET13 and capture Hi-C4,14 and in situ Hi-C15 were
mined to identify physical interactions between query SNPs and target gene
promoters. Variants were assigned to potential target genes based on intersection
with associated enhancer annotations using BedTools intersect57.
Table 4 Directional effect of genetically-determined gene expression on disease risk for predicted target genes of ER-negative
breast cancer sentinel risk variants
Direction of effect Predicted target genes of breast cancer sentinel risk variants
Decreased expression associated with decreased risk CCDC170, DDA1, KCNN4, PIK3C2B, RP5- 855D21.3, SMG9, ZNF703
Increased expression associated with decreased risk CCNE1, CENPO, CUL5, DNAJC27, ESR1, L3MBTL3, MCHR1, MDM4, NPAT, RALB, SYNE1
Ambiguous ADCY3
Table 5 Risk loci for ER-negative breast cancer identiﬁed in the EUGENE gene-based analysis and not in previous GWAS
Locus
Index
Gene Chr Start N sentinel eQTL Gene-based
P-valuea
Sentinel eQTL with strongest
association in adjusted GWAS
OncoScore
Tested with P < 0.05 in
adjusted GWAS*
Variant P-valueb
1 INHBB 2 121103719 3 2 1.13E−07 rs6542583 5.37E−06 25.82
2 TNFSF10 3 172223298 4 3 4.93E−07 rs2041692 5.66E−07 86.01
3 VPS52 6 33218049 2 1 1.01E−06 rs17215231 2.73E−07 17.45
4 GTF2IRD2B 7 74508364 1 1 8.52E−07 rs2259337 8.52E−07 0
aGene-based association P-value obtained when the EUGENE gene-based test was applied to the adjusted GWAS results
bP-value in the Milne et al. GWAS3, adjusted for (i) the association with the sentinel risk variants identiﬁed in this study using the COJO-COND test; and (ii) the LD-score intercept
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Identiﬁcation of previously unreported risk loci for breast cancer. The second
aim of this study was to use a gene-based approach to identify loci containing
breast cancer risk variants that were missed by the single-variant analyses reported
by Michailidou et al. 2. At least three gene-based approaches have been described
recently to combine in a single test the evidence for association with a disease
across multiple eQTL6,8,10. Of these, we opted to use EUGENE6,7 because it is
applicable to GWAS summary statistics and combines in the same association test
information from eQTL identiﬁed in different tissues and/or transcriptome studies.
The latter feature is important for two main reasons. First, because multiple tissue
types are likely to play a role in the pathophysiology of breast cancer, and tissue-
speciﬁc eQTL are common58. Second, because different transcriptome studies of
the same tissue (e.g. blood) identify partially (not completely) overlapping lists of
eQTL. This might arise, for example, because of differences in sample size, gene
expression quantiﬁcation methods (e.g. microarrays vs. RNA-seq, data normal-
ization) or demographics of the ascertained individuals (e.g. age, disease status).
Therefore, identifying eQTL based on information from multiple tissues and/or
studies is expected to produce a more comprehensive list of regulatory variants that
could be relevant to breast cancer pathophysiology. An additional advantage of
EUGENE is that it considers in the same test different types of eQTL (e.g. with
exon-speciﬁc or stimulus-speciﬁc effects), thereby increasing the likelihood that
causal regulatory variants related to breast cancer are captured in the analysis59.
EUGENE requires an input ﬁle that lists all eQTL that will be included in the
gene- based test for each gene. To generate such list for this study, we did as follows
for each gene in the genome. First, we took the union of all eQTL reported in the 86
eQTL datasets described above. Second, we used the --clump procedure in PLINK
to reduce the list of reported eQTL to a set of ‘sentinel eQTL’, deﬁned as the
variants with strongest association with gene expression and in low LD (r2 < 0.1,
LD window of 1 Mb) with each other. Note that clumping was not performed
separately for each tissue or study, but rather applied to the union of eQTL
identiﬁed across all tissues/studies. If an eQTL was identiﬁed in multiple tissues/
studies, the clumping procedure was performed using the smallest P-value reported
for that eQTL across all tissues/studies. A ﬁle (BREASTCANCER.20170517.eqtl.
proxies.list) containing the sentinel eQTL identiﬁed per gene is available at [https://
genepi.qimr.edu.au/staff/manuelF/eugene/main.html].
For each gene, EUGENE extracts single-variant association results for each
sentinel eQTL identiﬁed (or, if not available, for a proxy with r2 > 0.8) from the
GWAS summary statistics, sums the association chi-square values across those
eQTL, and estimates the signiﬁcance (i.e. P-value) of the resulting sum test statistic
using Satterthwaite's approximation, which accounts for the LD between eQTL7.
This approximation was originally implemented by Bakshi et al.60 in the GCTA-
fastBAT module and is now also available in EUGENE. LD between eQTL was
estimated based on data from 294 Europeans from the 1000 Genomes Project
(release 20130502_v5a).
Because our aim was to identify previously unreported breast cancer risk loci,
we did not apply EUGENE to the original results reported by Michailidou et al. 2.
Had we done so, signiﬁcant gene-based associations would have been
disproportionally located in known risk loci; associations driven by previously
unreported risk variants would therefore be more difﬁcult to highlight. Instead, we
ﬁrst adjusted the results2 for the effects of the sentinel risk variants identiﬁed (see
section above), using the --cojo-cond option of GCTA9. In doing so, we obtained
adjusted GWAS results with no single variant with an association P < 5 × 10−8. We
then applied EUGENE to the adjusted GWAS results, including a correction of
the single-variant association statistic (i.e. chi-square) for an LD-score regression
intercept61 of 1.1072. This correction was important to account for the inﬂation of
single-variant test statistics observed in Michailidou et al.2 that were likely due to
unaccounted biases.
To maintain the overall false-positive rate at 0.05, the signiﬁcance threshold
required to achieve experiment-wide signiﬁcance in the gene-based analysis was set
at P < 0.05/N genes tested.
OncoScore. We used OncoScore, a text-mining tool that ranks genes according
to their association with cancer based on available biomedical literature21, to
determine which of the breast cancer genes we identiﬁed were already known to
have a role in cancer.
ER-negative breast cancer. Lastly, we used the approaches described above to
identify target genes and previously unreported risk loci for ER-negative breast
cancer. In this case, single-variant summary association statistics were obtained
from the Milne et al.3 GWAS, which included 21,468 ER-negative cases and
100,594 controls from the Breast Cancer Association Consortium, combined with
18,908 BRCA1 mutation carriers (9414 with breast cancer) from the Consortium of
Investigators of Modiﬁers of BRCA1/2, all tested for 17,304,475 variants (9,827,195
after the exclusions described above). The LD-score regression intercept used to
correct the single-variant association statistics of this GWAS was 1.0637.
Study approval. Informed consent was obtained from all subjects participating in
the Breast Cancer Association Consortium under the approval of local Institutional
Review Boards. Ethics approval was obtained from the Human Research Ethics
Committee of QIMR-Berghofer.
Data availability
GWAS summary statistics analyzed in this study are available upon request from the
BCAC and CIMBA co-ordinators. The list of sentinel eQTL identiﬁed from publicly
available datasets are available for download from https://genepi.qimr.edu.au/staff/
manuelF/eugene/main.html.
Code availability
The EUGENE gene-based approach is implemented in C++ and is available for
download from https://genepi.qimr.edu.au/staff/manuelF/eugene/main.html.
Received: 18 May 2018 Accepted: 14 December 2018
References
1. Ginsburg, O. et al. The global burden of women's cancers: a grand challenge
in global health. Lancet 389, 847–860 (2017).
2. Michailidou, K. et al. Association analysis identiﬁes 65 new breast cancer
risk loci. Nature 551, 92–94 (2017).
3. Milne, R. L. et al. Identiﬁcation of ten variants associated with risk of estrogen-
receptor-negative breast cancer. Nat. Genet. 49, 1767–1778 (2017).
4. Javierre, B. M. et al. Lineage-speciﬁc genome architecture links enhancers and
non-coding disease variants to target gene promoters. Cell 167, 1369–1384 e19
(2016).
5. Teng, M. W., Swann, J. B., Koebel, C. M., Schreiber, R. D. & Smyth, M. J. Immune-
mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84, 988–993 (2008).
6. Ferreira, M. A. et al. Gene-based analysis of regulatory variants identiﬁes 4
putative novel asthma risk genes related to nucleotide synthesis and signaling.
J. Allergy Clin. Immunol. 139, 1148–1157 (2017).
7. Ferreira, M. A. R. et al. Eleven loci with new reproducible genetic associations
with allergic disease risk. J. Allergy Clin. Immunol. pii: S0091-6749(18)30558-
X. https://doi.org/10.1016/j.jaci.2018.03.012 (2018).
8. Gamazon, E. R. et al. A gene-based association method for mapping traits
using reference transcriptome data. Nat. Genet. 47, 1091–1098 (2015).
9. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary
statistics identiﬁes additional variants inﬂuencing complex traits. Nat. Genet.
44, 369–375 (2012). S1-3.
10. Barbeira, A. et al. Exploring the phenotypic consequences of tissue speciﬁc
gene expression variation inferred from GWAS summary statistics. bioRxiv
https://www.biorxiv.org/content/early/2017/10/03/045260 (2017).
11. Battle, A. et al. Characterizing the genetic basis of transcriptome diversity
through RNA-sequencing of 922 individuals. Genome Res. 24, 14–24 (2014).
12. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs:
illuminating the dark road from association to function. Am. J. Hum. Genet.
93, 779–797 (2013).
13. Li, G. et al. Extensive promoter-centered chromatin interactions provide a
topological basis for transcription regulation. Cell 148, 84–98 (2012).
14. Mifsud, B. et al. Mapping long-range promoter contacts in human cells with
high-resolution capture Hi-C. Nat. Genet. 47, 598–606 (2015).
15. Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals
principles of chromatin looping. Cell 159, 1665–1680 (2014).
16. Andersson, R. et al. An atlas of active enhancers across human cell types and
tissues. Nature 507, 455–461 (2014).
17. Corradin, O. et al. Combinatorial effects of multiple enhancer variants in
linkage disequilibrium dictate levels of gene expression to confer susceptibility
to common traits. Genome Res. 24, 1–13 (2014).
18. He, B., Chen, C., Teng, L. & Tan, K. Global view of enhancer-promoter
interactome in human cells. Proc. Natl Acad. Sci. USA 111, E2191–E2199 (2014).
19. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease.
Cell 155, 934–947 (2013).
20. Wu, L. et al. Identiﬁcation of novel susceptibility loci and genes for breast
cancer risk: a transcriptome-wide association study of 229,000 women of
European descent. Nat. Genet. 50, 968–978 (2018).
21. Piazza, R. et al. OncoScore: a novel, Internet-based tool to assess the oncogenic
potential of genes. Sci. Rep. 7, 46290 (2017).
22. Chun, S. et al. Limited statistical evidence for shared genetic effects of eQTLs
and autoimmune-disease-associated loci in three major immune-cell types.
Nat. Genet. 49, 600–605 (2017).
23. Criscitiello, C. et al. A gene signature to predict high tumour-inﬁltrating
lymphocytes after neoadjuvant chemotherapy and outcome in patients with
triple negative breast cancer. Ann. Oncol. 29, 162–169 (2018).
24. Stanford, S. M. & Bottini, N. PTPN22: the archetypal non-HLA autoimmunity
gene. Nat. Rev. Rheumatol. 10, 602–611 (2014).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications 11
25. Clarke, F. et al. The protein tyrosine phosphatase PTPN22 negatively regulates
presentation of immune complex derived antigens. Sci. Rep. 8, 12692
(2018).
26. Liu, J. et al. Rhomboid domain-containing protein 3 is a negative regulator of
TLR3- triggered natural killer cell activation. Proc. Natl Acad. Sci. USA 110,
7814–7819 (2013).
27. Liu, J. et al. Rhbdd3 controls autoimmunity by suppressing the production of
IL-6 by dendritic cells via K27-linked ubiquitination of the regulator NEMO.
Nat. Immunol. 15, 612–622 (2014).
28. Miyamoto, M. et al. Regulated expression of a gene encoding a nuclear factor,
IRF-1, that speciﬁcally binds to IFN-beta gene regulatory elements. Cell 54,
903–913 (1988).
29. Taniguchi, T., Ogasawara, K., Takaoka, A. & Tanaka, N. IRF family of
transcription factors as regulators of host defense. Annu. Rev. Immunol. 19,
623–655 (2001).
30. Holland, D. G. et al. ZNF703 is a common Luminal B breast cancer oncogene
that differentially regulates luminal and basal progenitors in human mammary
epithelium. EMBO Mol. Med. 3, 167–180 (2011).
31. Eriksson, N. et al. Genetic variants associated with breast size also inﬂuence
breast cancer risk. BMC Med. Genet. 13, 53 (2012).
32. Okumura, F., Joo-Okumura, A., Nakatsukasa, K. & Kamura, T. The role of
cullin 5-containing ubiquitin ligases. Cell Div. 11, 1 (2016).
33. Haupt, S. et al. The role of MDM2 and MDM4 in breast cancer development
and prevention. J. Mol. Cell Biol. 9, 53–61 (2017).
34. Caldon, C. E., Sergio, C. M., Sutherland, R. L. & Musgrove, E. A. Differences in
degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in
cancer cells. Cell Cycle 12, 596–605 (2013).
35. Rogers, S. et al. Cyclin E2 is the predominant E-cyclin associated with NPAT
in breast cancer cells. Cell Div. 10, 1 (2015).
36. Shalini, S., Dorstyn, L., Dawar, S. & Kumar, S. Old, new and emerging
functions of caspases. Cell Death Differ. 22, 526–539 (2015).
37. Chenevix-Trench, G. et al. Dominant negative ATM mutations in breast
cancer families. J. Natl. Cancer Inst. 94, 205–215 (2002).
38. Goldgar, D. E. et al. Rare variants in the ATM gene and risk of breast cancer.
Breast Cancer Res. 13, R73 (2011).
39. Magnani, L. & Lupien, M. Chromatin and epigenetic determinants of
estrogen receptor alpha (ESR1) signaling. Mol. Cell Endocrinol. 382, 633–641
(2014).
40. Raza, H. Dual localization of glutathione S-transferase in the cytosol and
mitochondria: implications in oxidative stress, toxicity and disease. FEBS J.
278, 4243–4251 (2011).
41. Samanta, S. et al. IMP3 promotes stem-like properties in triple-negative breast
cancer by regulating SLUG. Oncogene 35, 1111–1121 (2016).
42. Esplin, E. D. et al. The glycine 90 to aspartate alteration in the Abeta subunit
of PP2A (PPP2R1B) associates with breast cancer and causes a deﬁcit in
protein function. Genes Chromosomes Cancer 45, 182–190 (2006).
43. Petrovic, A. et al. Structure of the MIS12 complex and molecular basis of its
interaction with CENP-C at human kinetochores. Cell 167, 1028–1040 e15
(2016).
44. Sun, T. et al. A reverse signaling pathway downstream of Sema4A controls cell
migration via Scrib. J. Cell Biol. 216, 199–215 (2017).
45. Hoffman, J. D. et al. Cis-eQTL-based trans-ethnic meta-analysis reveals
novel genes associated with breast cancer risk. PLoS Genet. 13, e1006690
(2017).
46. Chikh, A. et al. Class II phosphoinositide 3-kinase C2beta regulates a novel
signaling pathway involved in breast cancer progression. Oncotarget 7,
18325–18345 (2016).
47. Yu, X. et al. Structure, inhibitor, and regulatory mechanism of Lyp, a
lymphoid- speciﬁc tyrosine phosphatase implicated in autoimmune diseases.
Proc. Natl Acad. Sci. USA 104, 19767–19772 (2007).
48. Shaye, A. et al. Cyclin E deregulation is an early event in the development of
breast cancer. Breast Cancer Res. Treat. 115, 651–659 (2009).
49. Navaratnam, N. & Sarwar, R. An overview of cytidine deaminases. Int. J.
Hematol. 83, 195–200 (2006).
50. French, J. D. et al. Functional variants at the 11q13 risk locus for breast cancer
regulate cyclin D1 expression through long-range enhancers. Am. J. Hum.
Genet. 92, 489–503 (2013).
51. Ataga, K. I. et al. Improvements in haemolysis and indicators of erythrocyte
survival do not correlate with acute vaso-occlusive crises in patients with sickle
cell disease: a phase III randomized, placebo-controlled, double-blind study of
the Gardos channel blocker senicapoc (ICA-17043). Br. J. Haematol. 153,
92–104 (2011).
52. Pierce, B. L. et al. Mediation analysis demonstrates that trans-eQTLs are often
explained by cis-mediation: a genome-wide analysis among 1,800 South
Asians. PLoS Genet. 10, e1004818 (2014).
53. Davis, J. R. et al. An efﬁcient multiple-testing adjustment for eQTL studies
that accounts for linkage disequilibrium between variants. Am. J. Hum. Genet.
98, 216–224 (2016).
54. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers
functional variation in humans. Nature 501, 506–511 (2013).
55. Montgomery, S. B. et al. Transcriptome genetics using second generation
sequencing in a Caucasian population. Nature 464, 773–777 (2010).
56. Bycroft, C. et al. TheUK Biobank resource with deep phenotyping and
genomic data. Nature 562, 203–209 (2018).
57. Quinlan, A. R. & Hall, I. M. BEDTools: a ﬂexible suite of utilities for
comparing genomic features. Bioinformatics 26, 841–842 (2010).
58. Consortium, G. T. et al. Genetic effects on gene expression across human
tissues. Nature 550, 204–213 (2017).
59. Odhams, C. A., Cunninghame Graham, D. S. & Vyse, T. J. Proﬁling RNA-Seq
at multiple resolutions markedly increases the number of causal eQTLs in
autoimmune disease. PLoS Genet. 13, e1007071 (2017).
60. Bakshi, A. et al. Fast set-based association analysis using summary data from
GWAS identiﬁes novel gene loci for human complex traits. Sci. Rep. 6, 32894
(2016).
61. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding
from polygenicity in genome-wide association studies. Nat. Genet. 47,
291–295 (2015).
Acknowledgements
Full details of the Acknowledgements are provided in Supplementary Note 1.
Author contributions
Writing Group: M.A.F., F. Al-E., W.Z., D.F.E., R.L.M., J.B., G.C.-T.; Statistical analysis: M.F.
and E.R.G.; Provided DNA samples and/or phenotypic data: K.A., I.L.A., H.A.-C., A.C.A,
A.A., V.A., K.J.A., B.K.A., E.A., J.A., J.B., D.R.B., D.B., M.W.B., S.B.,J.B., M.B., C.B., N.V.B.,
S.E.B., M.K.B., A.B., H.B., H.B., A.B., B.B., T.C., M.A.C., I.C., F.C., J.C., B.D.C., J.E.C., J.C.-C.,
D.C., H.C., W.K.C., K.B.M.C., C.L.C., F.J.C., A.C., S.J.C., S.S.C., K.C., M.B.D., M. de la H.,
J.D., P.D., O.D., T.D., A.M.D., M.D., D.M.E., B.E., C.E., C.E., M.E., P.A.F., O.F., H.F., E.F.,
D.F., M.G., M.G.-D., P.A.G., S.M.G., J.G., M.G.-C., J.A.G.-S., M.M.G., G.G.G., G.G., A.K.G.,
M.S.G., D.E.G., A.G.-N., M.H.G., J.G., P.G., C.A.H., P.H., U.H., W.H., J.H., F.B.L.H., A.H.,
R.N.H., J.L.H., P.J.H., K.H., E.N.I., C.I., M.J., A.J., P.J., R.J., R.C.J., E.M.J., N.J., M.E.J., V.J.,
K.B., B.Y.K., T.K., E.K., J.I.K., Y.-D.K., I.K., P.K., V.N.K., Y.L., D.L., C.L., G.L., J.L., F.L., S.L.,
J.L., J.T.L., J.L., E.M., A.M., S.M., D.M., L.M.,A.M., U.M., K.M., A.M., M.M., F.M., L.M.,
A.M.M., K.L.N., S.L.N., H.N., I.N., F.C.N., L.N.-Z., K.O., E.O., O.L.O., H.O., A.O., J.P.,
T.-W.P.-S., M.T.P., IS.P., A.P.,P.P., P.D.P.P., D.P.K., B.P., N.P., P.R., J.R., G.R., H.A.R., E.S.,
K.S., E.J.S., M.K.S., R.K.S., P.S., X.-O.S., J.S., C.F.S., P.S., M.C.S., J.J.S., A.B.S., J.S., A.J.S.,
W.J.T., J.A.T., M.R.T., MB.T., A.Te., M.T., K.T., D.L.T., M.T., A.E.T., D.T., T.T., N.T.,
C.M.V., R.L.N., C.J.VA., A.M.W. van den O., E.J.VR., A.V., A.V., Q.W., B.W., J.N.W., C.W.,
R.W., X.R.Y., D.Y., A.Z., M.M., GEMO Study Collaborators, GC-HBOC study Collabora-
tors, EMBRACE Collaborators, HEBON Investigators, BCFR Investigators and ABCTB
Investigators.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-08053-5.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks the anonymous
reviewers for their contribution to the peer review of this work. Peer reviewer reports are
available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5
12 NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications
Manuel A. Ferreira1, Eric R. Gamazon 2,3, Fares Al-Ejeh1, Kristiina Aittomäki4, Irene L. Andrulis 5,6,
Hoda Anton-Culver7, Adalgeir Arason 8,9, Volker Arndt 10, Kristan J. Aronson11, Banu K. Arun12,
Ella Asseryanis13, Jacopo Azzollini14, Judith Balmaña15,16, Daniel R. Barnes 17, Daniel Barrowdale17,
Matthias W. Beckmann18, Sabine Behrens19, Javier Benitez20,21, Marina Bermisheva22, Katarzyna Białkowska23,
Carl Blomqvist24,25, Natalia V. Bogdanova26,27,28, Stig E. Bojesen 29,30,31, Manjeet K. Bolla17, Ake Borg32,
Hiltrud Brauch33,34,35, Hermann Brenner10,35,36, Annegien Broeks37, Barbara Burwinkel38,39, Trinidad Caldés40,
Maria A. Caligo41, Daniele Campa19,42, Ian Campbell 43,44, Federico Canzian45, Jonathan Carter46,
Brian D. Carter47, Jose E. Castelao48, Jenny Chang-Claude19,49, Stephen J. Chanock 50, Hans Christiansen26,
Wendy K. Chung51, Kathleen B.M. Claes 52, Christine L. Clarke53, GC-HBOC Study Collaborators,
GEMO Study Collaborators, EMBRACE Collaborators, Fergus J. Couch54, Angela Cox55, Simon S. Cross56,
Kamila Czene57, Mary B. Daly58, Miguel de la Hoya40, Joe Dennis 17, Peter Devilee 59,60, Orland Diez15,61,
Thilo Dörk27, Alison M. Dunning62, Miriam Dwek63, Diana M. Eccles64, Bent Ejlertsen65, Carolina Ellberg 66,
Christoph Engel67, Mikael Eriksson57, Peter A. Fasching 18,68, Olivia Fletcher 69, Henrik Flyger70,
Eitan Friedman71,72, Debra Frost17, Marike Gabrielson57, Manuela Gago-Dominguez73,74, Patricia A. Ganz75,
Susan M. Gapstur47, Judy Garber76, Montserrat García-Closas50,77, José A. García-Sáenz 78, Mia M. Gaudet47,
Graham G. Giles79,80,81, Gord Glendon5, Andrew K. Godwin82, Mark S. Goldberg83,84, David E. Goldgar85,
Anna González-Neira21, Mark H. Greene 86, Jacek Gronwald23, Pascal Guénel 87, Christopher A. Haiman88,
Per Hall57,89, Ute Hamann90, Wei He57, Jane Heyworth91, Frans B.L. Hogervorst92, Antoinette Hollestelle 93,
Robert N. Hoover50, John L. Hopper80, Peter J. Hulick 94,95, Keith Humphreys57,
Evgeny N. Imyanitov96, HEBON Investigators, BCFR Investigators, ABCTB Investigators, Claudine Isaacs97,
Milena Jakimovska 98, Anna Jakubowska23,99, Paul A. James 44,100, Ramunas Janavicius101,
Rachel C. Jankowitz102, Esther M. John103, Nichola Johnson69, Vijai Joseph 104, Beth Y. Karlan105,
Elza Khusnutdinova22,106, Johanna I. Kiiski107, Yon-Dschun Ko108, Michael E. Jones109, Irene Konstantopoulou110,
Vessela N. Kristensen111,112, Yael Laitman71, Diether Lambrechts 113,114, Conxi Lazaro115, Goska Leslie 17,
Jenny Lester105, Fabienne Lesueur116,117,118, Sara Lindström119,120, Jirong Long121, Jennifer T. Loud86, Jan Lubiński23,
Enes Makalic80, Arto Mannermaa122,123,124, Mehdi Manoochehri90, Sara Margolin89,125, Tabea Maurer49,
Dimitrios Mavroudis126, Lesley McGuffog17, Alfons Meindl127, Usha Menon 128, Kyriaki Michailidou 17,129,
Austin Miller 130, Marco Montagna131, Fernando Moreno78, Lidia Moserle131, Anna Marie Mulligan132,133,
Katherine L. Nathanson 134, Susan L. Neuhausen135, Heli Nevanlinna 107, Ines Nevelsteen136,
Finn C. Nielsen137, Liene Nikitina-Zake 138, Robert L. Nussbaum139, Kenneth Ofﬁt104,140, Edith Olah141,
Olufunmilayo I. Olopade 142, Håkan Olsson66, Ana Osorio20,21, Janos Papp141, Tjoung-Won Park-Simon27,
Michael T. Parsons 1, Inge Sokilde Pedersen 143,144,145, Ana Peixoto146, Paolo Peterlongo147,
Paul D.P. Pharoah 17,62, Dijana Plaseska-Karanﬁlska98, Bruce Poppe52, Nadege Presneau63, Paolo Radice148,
Johanna Rantala149, Gad Rennert 150, Harvey A. Risch151, Emmanouil Saloustros 152, Kristin Sanden153,
Elinor J. Sawyer154, Marjanka K. Schmidt 37,155, Rita K. Schmutzler156,157, Priyanka Sharma158, Xiao-Ou Shu121,
Jacques Simard159, Christian F. Singer13, Penny Soucy159, Melissa C. Southey160,161, John J. Spinelli 162,163,
Amanda B. Spurdle1, Jennifer Stone 80,164, Anthony J. Swerdlow109,165, William J. Tapper64, Jack A. Taylor166,167,
Manuel R. Teixeira 146,168, Mary Beth Terry169, Alex Teulé170, Mads Thomassen171, Kathrin Thöne49,
Darcy L. Thull172, Marc Tischkowitz173,174, Amanda E. Toland 175, Diana Torres90,176, Thérèse Truong 87,
Nadine Tung177, Celine M. Vachon178, Christi J. van Asperen179, Ans M.W. van den Ouweland180,
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications 13
Elizabeth J. van Rensburg181, Ana Vega182, Alessandra Viel 183, Qin Wang17, Barbara Wappenschmidt156,157,
Jeffrey N. Weitzel184, Camilla Wendt125, Robert Winqvist185,186, Xiaohong R. Yang50, Drakoulis Yannoukakos110,
Argyrios Ziogas 7, Peter Kraft187,188, Antonis C. Antoniou17, Wei Zheng121, Douglas F. Easton 17,62,
Roger L. Milne79,80,160, Jonathan Beesley 1 & Georgia Chenevix-Trench1
1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. 2Division of
Genetic Medicine, Department of Medicine, Vanderbilt University, Nashville, TN 37235, USA. 3Clare Hall, University of Cambridge, Cambridge CB3
9AL, UK. 4Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, 00290 Helsinki, Finland. 5Fred A. Litwin Center for
Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada. 6Department of Molecular
Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. 7Department of Epidemiology, Genetic Epidemiology Research Institute, University
of California Irvine, Irvine, CA, USA 92617. 8Department of Pathology, Landspitali University Hospital, 101 Reykjavik, Iceland. 9BMC (Biomedical
Centre), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland. 10Division of Clinical Epidemiology and Aging Research, C070, German
Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 11Department of Public Health Sciences, and Cancer Research Institute, Queen’s
University, Kingston, ON K7L 3N6, Canada. 12Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston,
TX 77030, USA. 13Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. 14Unit of Medical
Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), 20133 Milan, Italy.
15Oncogenetics Group, Vall dHebron Institute of Oncology (VHIO), 8035 Barcelona, Spain. 16Department of Medical Oncology, Vall d’Hebron
Institute of Oncology (VHIO), University Hospital, Vall d’Hebron, 08035 Barcelona, Spain. 17Centre for Cancer Genetic Epidemiology, Department
of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. 18Department of Gynecology and Obstetrics, Comprehensive
Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, 91054 Erlangen, Germany. 19Division of
Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 20Centro de Investigación en Red de Enfermedades
Raras (CIBERER), 46010 Valencia, Spain. 21Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), 28029 Madrid,
Spain. 22Institute of Biochemistry and Genetics, Ufa Federal Research Centre of Russian Academy of Sciences, 450054 Ufa, Russia. 23Department
of Genetics and Pathology, Pomeranian Medical University, 71-252 Szczecin, Poland. 24Department of Oncology, Helsinki University Hospital,
University of Helsinki, Helsinki 00290, Finland. 25Department of Oncology, Örebro University Hospital, 70185 Örebro, Sweden. 26Department of
Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany. 27Gynaecology Research Unit, Hannover Medical School, 30625
Hannover, Germany. 28N.N. Alexandrov Research Institute of Oncology and Medical Radiology, 223040 Minsk, Belarus. 29Copenhagen General
Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark. 30Department of Clinical Biochemistry,
Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark. 31Faculty of Health and Medical Sciences, University of
Copenhagen, 2200 Copenhagen, Denmark. 32Department of Oncology, Lund University and Skåne University Hospital, 222 41 Lund, Sweden. 33Dr.
Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 70376 Stuttgart, Germany. 34University of Tübingen, 72074 Tübingen, Germany.
35German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 36Division of Preventive Oncology,
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany. 37Division of Molecular
Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands. 38Molecular
Epidemiology Group, C080, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 39Molecular Biology of Breast Cancer,
University Womens Clinic Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany. 40Molecular Oncology Laboratory, CIBERONC,
Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), 28040 Madrid, Spain. 41Section of
Molecular Genetics, Dept. of Laboratory Medicine, University Hospital of Pisa, 56126 Pisa, Italy. 42Department of Biology, University of Pisa, 56126
Pisa, Italy. 43Research Department, Peter MacCallum Cancer Center, Melbourne, VIC 3000, Australia. 44Sir Peter MacCallum Department of
Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia. 45Genomic Epidemiology Group, German Cancer Research Center
(DKFZ), 69120 Heidelberg, Germany. 46Department of Gynaecological Oncology, Chris O’Brien Lifehouse and The University of Sydney,
Camperdown, NSW 2050, Australia. 47Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA 30303.
48Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, 36312 Vigo,
Spain. 49Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, 20246
Hamburg, Germany. 50Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health
and Human Services, Bethesda, MD 20850, USA. 51Departments of Pediatrics and Medicine, Columbia University, New York, NY 10032, USA.
52Centre for Medical Genetics, Ghent University, Gent 9000, Belgium. 53Westmead Institute for Medical Research, University of Sydney, Sydney,
NSW 2145, Australia. 54Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. 55Shefﬁeld Institute for
Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Shefﬁeld, Shefﬁeld S10 2TN, UK. 56Academic Unit of Pathology,
Department of Neuroscience, University of Shefﬁeld, Shefﬁeld S10 2TN, UK. 57Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, 171 65 Stockholm, Sweden. 58Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 59Department of
Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. 60Department of Human Genetics, Leiden University Medical
Center, 2333 ZA Leiden, The Netherlands. 61Clinical and Molecular Genetics Area, University Hospital Vall dHebron, Barcelona 08035, Spain.
62Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. 63Department of
Biomedical Sciences, Faculty of Science and Technology, University of Westminster, London W1B 2HW, UK. 64Faculty of Medicine, University of
Southampton, Southampton SO17 1BJ, UK. 65Department of Oncology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen,
Denmark. 66Department of Cancer Epidemiology, Clinical Sciences, Lund University, 222 42 Lund, Sweden. 67Institute for Medical Informatics,
Statistics and Epidemiology, University of Leipzig, 04107 Leipzig, Germany. 68David Geffen School of Medicine, Department of Medicine Division of
Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA. 69The Breast Cancer Now Toby Robins Research
Centre, The Institute of Cancer Research, London SW7 3RP, UK. 70Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen
University Hospital, 2730 Herlev, Denmark. 71The Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, 52621 Ramat Gan, Israel.
72Sackler Faculty of Medicine, Tel Aviv University, 69978 Ramat Aviv, Israel. 73Genomic Medicine Group, Galician Foundation of Genomic
Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, 15706
Santiago de Compostela, Spain. 74Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA. 75Schools of Medicine and
Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Centre, UCLA, Los Angeles, CA 90096-6900,
USA. 76Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 77Division of Genetics and Epidemiology,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5
14 NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications
Institute of Cancer Research, London SM2 5NG, UK. 78Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación
Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), 28040 Madrid, Spain. 79Cancer Epidemiology &
Intelligence Division, Cancer Council Victoria, Melbourne, VIC 3004, Australia. 80Centre for Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of Melbourne, Melbourne, VIC 3010, Australia. 81Department of Epidemiology and Preventive
Medicine, Monash University, Melbourne, VIC 3004, Australia. 82Department of Pathology and Laboratory Medicine, Kansas University Medical
Center, Kansas City, KS 66160, USA. 83Department of Medicine, McGill University, Montréal, QC H4A 3J1, Canada. 84Division of Clinical
Epidemiology, Royal Victoria Hospital, McGill University, Montréal, QC H4A 3J1, Canada. 85Department of Dermatology, Huntsman Cancer
Institute, University of Utah School of Medicine, Salt Lake City, UT 84112, USA. 86Clinical Genetics Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, Bethesda, MD 20850-9772, USA. 87Cancer & Environment Group, Center for Research in Epidemiology and
Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, 94805 Villejuif, France. 88Department of Preventive Medicine,
Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. 89Department of Oncology, Södersjukhuset, 118 83
Stockholm, Sweden. 90Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. 91School of
Population and Global Health, The University of Western Australia, Perth, WA 6009, Australia. 92Family Cancer Clinic, The Netherlands Cancer
Institute - Antoni van Leeuwenhoek hospital, Amsterdam 1066 CX, The Netherlands. 93Department of Medical Oncology, Family Cancer Clinic,
Erasmus MC Cancer Institute, Rotterdam 3015 CN, The Netherlands. 94Center for Medical Genetics, NorthShore University HealthSystem,
Evanston, IL 60201, USA. 95The University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA. 96N.N. Petrov Institute of Oncology. St.,
Petersburg 197758, Russia. 97Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA. 98Research Centre
for Genetic Engineering and Biotechnology ‘Georgi D. Efremov’, Macedonian Academy of Sciences and Arts, Skopje 1000, Republic of Macedonia.
99Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin 71-252, Poland. 100Parkville
Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, VIC 3000, Australia. 101Hematology, oncology and transfusion medicine
center, Dept. of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius 08410, Lithuania. 102Department of
Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232,
USA. 103Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304,
USA. 104Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY
10065, USA. 105David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles,
CA 90095, USA. 106Department of Genetics and Fundamental Medicine, Bashkir State Medical University, 450076 Ufa, Russia. 107Department of
Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki 00290, Finland. 108Department of Internal Medicine,
Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn 53177, Germany. 109Division of Genetics and Epidemiology, The Institute of
Cancer Research, London SM2 5NG, UK. 110Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientiﬁc Research ‘Demokritos’,
Athens 15310, Greece. 111Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo 0379,
Norway. 112Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo 0450, Norway. 113VIB Center for Cancer Biology, VIB, Leuven
3001, Belgium. 114Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven 3000, Belgium. 115Molecular
Diagnostic Unit, Hereditary Cancer Program, ICO-IDIBELL (Bellvitge Biomedical Research Institute, Catalan Institute of Oncology), CIBERONC,
Barcelona 08908, Spain. 116Genetic Epidemiology of Cancer team, Inserm U900, Paris 75005, France. 117Institut Curie, Paris 75005, France.
118Mines ParisTech, Fontainebleau 77305, France. 119Department of Epidemiology, University of Washington School of Public Health, Seattle, WA
98195, USA. 120Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 121Division of Epidemiology,
Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville,
TN 37232, USA. 122Translational Cancer Research Area, University of Eastern Finland, Kuopio 70210, Finland. 123Institute of Clinical Medicine,
Pathology and Forensic Medicine, University of Eastern Finland, Kuopio 70210, Finland. 124Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, Kuopio 70210, Finland. 125Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm 118
83, Sweden. 126Department of Medical Oncology, University Hospital of Heraklion, Heraklion 711 10, Greece. 127Department of Gynecology and
Obstetrics, University of Munich, Campus Großhadern, Munich 81377, Germany. 128MRC Clinical Trials Unit at UCL, Institute of Clinical Trials &
Methodology, University College London, London WC1V 6LJ, UK. 129Department of Electron Microscopy/Molecular Pathology and The Cyprus
School of Molecular Medicine, The Cyprus Institute of Neurology & Genetics, Nicosia 1683, Cyprus. 130NRG Oncology, Statistics and Data
Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. 131Immunology and Molecular Oncology Unit, Veneto Institute of
Oncology IOV - IRCCS, Padua 35128, Italy. 132Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8,
Canada. 133Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada. 134Basser Center for BRCA, Abramson
Cancer Center, University of Pennsylvania, Philadelphia, PA 19066, USA. 135Department of Population Sciences, Beckman Research Institute of City
of Hope, Duarte, CA 91010, USA. 136Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals
Leuven, Leuven 3000, Belgium. 137Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen DK-2100, Denmark.
138Latvian Biomedical Research and Study Centre, Riga LV-1067, Latvia. 139Cancer Genetics and Prevention Program, University of California San
Francisco, San Francisco, CA 94143-1714, USA. 140Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center,
New York, NY 10065, USA. 141Department of Molecular Genetics, National Institute of Oncology, Budapest 1122, Hungary. 142Center for Clinical
Cancer Genetics, The University of Chicago, Chicago, IL 60637, USA. 143Molecular Diagnostics, Aalborg University Hospital, Aalborg 9000,
Denmark. 144Clinical Cancer Research Center, Aalborg University Hospital, Aalborg 9000, Denmark. 145Department of Clinical Medicine, Aalborg
University, Aalborg 9000, Denmark. 146Department of Genetics, Portuguese Oncology Institute, Porto 4220-072, Portugal. 147Genome Diagnostics
Program, IFOM - the FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan 20139, Italy. 148Unit of Molecular Bases
of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan 20133, Italy. 149Clinical
Genetics, Karolinska Institutet, Stockholm 171 76, Sweden. 150Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of
Medicine, Haifa 35254, Israel. 151Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT 06510, USA. 152Department of
Oncology, University Hospital of Larissa, Larissa 411 10, Greece. 153City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA
91010, USA. 154Research Oncology, Guy’s Hospital, King’s College London, London SE1 9RT, UK. 155Division of Psychosocial Research and
Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam 1066 CX, The Netherlands. 156Center for
Hereditary Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.
157Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
158Department of Internal Medicine, Division of Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA. 159Genomics Center,
Centre Hospitalier Universitaire de Québec – Université Laval, Research Center, Québec City, QC G1V 4G2, Canada. 160Precision Medicine, School
of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia. 161Department of Clinical Pathology, The University of
Melbourne, Melbourne, VIC 3010, Australia. 162Population Oncology, BC Cancer, Vancouver, BC V5Z 1G1, Canada. 163School of Population and
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications 15
Public Health, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. 164The Curtin UWA Centre for Genetic Origins of Health and
Disease, Curtin University and University of Western Australia, Perth, WA 6000, Australia. 165Division of Breast Cancer Research, The Institute of
Cancer Research, London SW7 3RP, UK. 166Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park,
NC 27709, USA. 167Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park,
NC 27709, USA. 168Biomedical Sciences Institute (ICBAS), University of Porto, Porto 4050-013, Portugal. 169Department of Epidemiology, Mailman
School of Public Health, Columbia University, New York, NY 10032, USA. 170Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL
(Bellvitge Biomedical Research Institute),Catalan Institute of Oncology, CIBERONC, Barcelona 08908, Spain. 171Department of Clinical Genetics,
Odense University Hospital, Odence C 5000, Denmark. 172Department of Medicine, Magee-Womens Hospital, University of Pittsburgh School of
Medicine, Pittsburgh, PA 15213, USA. 173Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal,
QC H4A 3J1, Canada. 174Department of Medical Genetics, University of Cambridge, Cambridge CB2 0QQ, UK. 175Department of Cancer Biology
and Genetics, The Ohio State University, Columbus, OH 43210, USA. 176Institute of Human Genetics, Pontiﬁcia Universidad Javeriana, Bogota
110231, Colombia. 177Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. 178Department of Health
Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN 55905, USA. 179Department of Clinical Genetics, Leiden University
Medical Center, Leiden 2333 ZA, The Netherlands. 180Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 CN,
The Netherlands. 181Department of Genetics, University of Pretoria, Arcadia 0007, South Africa. 182Fundación Pública galega Medicina Xenómica-
SERGAS, Grupo de Medicina Xenómica-USC, CIBERER, IDIS, Santiago de Compostela, Spain. 183Division of Functional onco-genomics and genetics,
Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081, Italy. 184Clinical Cancer Genomics, City of Hope, Duarte, CA 91010, USA.
185Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu
90570, Finland. 186Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu 90570, Finland. 187Program in
Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston 02115 MA, USA. 188Department of Epidemiology,
Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
GC-HBOC Study Collaborators
Norbert Arnold221,222, Bernd Auber223, Nadja Bogdanova-Markov224, Julika Borde156,157,225, Almuth Caliebe226,
Nina Ditsch127, Bernd Dworniczak224, Stefanie Engert227, Ulrike Faust228, Andrea Gehrig229, Eric Hahnen156,157,
Jan Hauke156,157, Julia Hentschel230, Natalie Herold156,157,225, Ellen Honisch231, Walter Just232, Karin Kast233,
Mirjam Larsen156,157, Johannes Lemke230, Huu Phuc Nguyen228, Dieter Niederacher231, Claus-Eric Ott234,
Konrad Platzer230, Esther Pohl-Rescigno156,157, Juliane Ramser227, Kerstin Rhiem156,157, Doris Steinemann223,
Christian Sutter235, Raymonda Varon-Mateeva234, Shan Wang-Gohrke236 & Bernhard H.F. Weber237
221Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel
24118, Germany. 222Institute of Clinical Molecular Biology, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University
Kiel, 24118 Kiel, Germany. 223Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany. 224Institute of Human Genetics,
University of Münster, Münster 48149, Germany. 225Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital
Cologne, University of Cologne, Cologne 50931, Germany. 226Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel,
Christian-Albrechts University Kiel, Kiel 24118, Germany. 227Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen
Universität München, Munich 80333, Germany. 228Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72074,
Germany. 229Department of Human Genetics, University Würzburg, Würzburg 97074, Germany. 230Institute of Human Genetics, University
Hospital Leipzig, Leipzig 04103, Germany. 231Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University
Düsseldorf, Düsseldorf 40225, Germany. 232Institute of Human Genetics, University Hospital Ulm, Ulm 89075, Germany. 233Department of
Gynecology and Obstetrics, Technical University of Dresden, Dresden 01307, Germany. 234Institute of Human Genetics, Campus Virchov Klinikum,
Charite, Berlin 13353, Germany. 235Institute of Human Genetics, University Hospital Heidelberg, 69120 Heidelberg, Germany. 236Department of
Gynaecology and Obstetrics, University Hospital Ulm, 89075 Ulm, Germany. 237Institute of Human Genetics, University Regensburg, 93053
Regensberg, Germany
GEMO Study Collaborators
Fabienne Prieur238, Pascal Pujol239, Charlotte Sagne240, Nicolas Sevenet241, Hagay Sobol242,243,
Johanna Sokolowska244, Dominique Stoppa-Lyonnet245,246,247 & Laurence Venat-Bouvet248
238Service de Génétique Clinique Chromosomique et Moléculaire, Hôpital Nord, CHU Saint Etienne, 42270 St. Etienne, France. 239Unité
d’Oncogénétique, CHU Arnaud de Villeneuve, 34295 Montpellier, France. 240Bâtiment Cheney D, Centre Léon Bérard, Lyon 69373, France.
241Oncogénétique, Institut Bergonié, Bordeaux 33076, France. 242Département Oncologie Génétique, Prévention et Dépistage, Institut Paoli-
Calmettes, Marseille 13009, France. 243Marseille Medical School, Aix-Marseille University, Marseille 13007, France. 244Laboratoire de génétique
médicale, Nancy Université, Centre Hospitalier Régional et Universitaire, Vandoeuvre-les-Nancy 54511, France. 245Service de Génétique, Institut
Curie, Paris 75005, France. 246Department of Tumour Biology, INSERM U830, 75005 Paris, France. 247Université Paris Descartes, 75006 Paris,
France. 248Department of Medical Oncology, CHU Dupuytren, Limoges 87042, France
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5
16 NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications
EMBRACE Collaborators
Julian Adlard195, Munaza Ahmed196, Julian Barwell197, Angela Brady198, Carole Brewer199, Jackie Cook200,
Rosemarie Davidson201, Alan Donaldson202, Jacqueline Eason203, Ros Eeles204, D. Gareth Evans205,206,
Helen Gregory207, Helen Hanson208, Alex Henderson209, Shirley Hodgson210, Louise Izatt211,
M. John Kennedy212, Fiona Lalloo206, Clare Miller213, Patrick J. Morrison214, Kai-ren Ong215, Jo Perkins17,
Mary E. Porteous216, Mark T. Rogers217, Lucy E. Side218, Katie Snape219, Lisa Walker220 & Patricia A. Harrington62
195Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds LS7 4SA, UK. 196North East Thames Regional Genetics Service, Great
Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK. 197Leicestershire Clinical Genetics Service, University Hospitals of Leicester
NHS Trust, Leicester LE1 5WW, UK. 198North West Thames Regional Genetics Service, Kennedy Galton Centre, The North West London Hospitals
NHS Trust, Middlesex HA1 3UJ, UK. 199Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter EX2 5DW, UK. 200Shefﬁeld Clinical
Genetics Service, Shefﬁeld Children’s Hospital, Shefﬁeld S10 2TH, UK. 201Department of Clinical Genetics, South Glasgow University Hospitals,
Glasgow G51 4TF, UK. 202Clinical Genetics Department, St. Michael’s Hospital, Bristol BS2 8EG, UK. 203Nottingham Clinical Genetics Service,
Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK. 204Oncogenetics Team, The Institute of Cancer Research and Royal
Marsden NHS Foundation Trust, London SM2 5NG, UK. 205Genomic Medicine, Division of Evolution and Genomic Sciences, The University of
Manchester, Manchester Academic Health Science Centre, Manchester Universities Foundation Trust, St. Mary’s Hospital, Manchester M13 9WL,
UK. 206Genomic Medicine, North West Genomics hub, Manchester Academic Health Science Centre, Manchester Universities Foundation Trust,
St. Mary’s Hospital, Manchester M13 9WL, UK. 207North of Scotland Regional Genetics Service, NHS Grampian & University of Aberdeen,
Foresterhill, Aberdeen, UK. 208Southwest Thames Regional Genetics Service, St. George’s Hospital, London SW17 0QT, UK. 209Institute of Genetic
Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne NE1 3BZ, UK. 210Department of Clinical Genetics, St
George’s, University of London, London SW17 0RE, UK. 211Clinical Genetics, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK.
212Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin and St. James’s Hospital, Dublin, Eire 8, Ireland. 213Department of
Clinical Genetics, Alder Hey Hospital, Liverpool L12 2AP, UK. 214Northern Ireland Regional Genetics Centre, Belfast City Hospital, Belfast BT9 7AB,
UK. 215West Midlands Regional Genetics Service, Birmingham Women’s Hospital Healthcare NHS Trust, Birmingham B15 2TG, UK. 216South East
of Scotland Regional Genetics Service, Western General Hospital, Edinburgh EH4 2XU, UK. 217All Wales Medical Genetics Services, University
Hospital of Wales, Cardiff CF14 4XW, UK. 218Princess Anne Hospital, Southampton SO16 5YA, UK. 219Medical Genetics Unit, St. George’s,
University of London, London SW17 0RE, UK. 220Oxford Regional Genetics Service, Churchill Hospital, Oxford OX3 7LJ, UK
HEBON Investigators
Bernadette A.M. Heemskerk-Gerritsen93, Matti A. Rookus249, Caroline M. Seynaeve93,
Frederieke H. van der Baan249, Annemieke H. van der Hout250, Lizet E. van der Kolk92, Rob B. van der Luijt251,
Carolien H.M. van Deurzen252, Helena C. van Doorn253, Klaartje van Engelen254, Liselotte van Hest255,
Theo A.M. van Os256, Senno Verhoef92, Maartje J. Vogel257 & Juul T. Wijnen258
249Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. 250Department of Genetics, University
Medical Center Groningen, University Groningen, Groningen 9713 GZ, The Netherlands. 251Department of Medical Genetics, University Medical
Center, Utrecht 3594 CX, The Netherlands. 252Department of Pathology, Erasmus University Medical Center, Rotterdam 3015 CN, The
Netherlands. 253Department of Gynaecology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam 3015 CE, The Netherlands.
254Department of Clinical Genetics, VU University Medical Center, Amsterdam 1105 AZ, The Netherlands. 255Clinical Genetics, Amsterdam UMC,
Vrije Universiteit Amsterdam, Amsterdam 1007 MB, The Netherlands. 256Department of Clinical Genetics, Amsterdam UMC, location AMC,
Amsterdam 1100 DD, The Netherlands. 257Department of Pathology, Netherlands Cancer Institute, Amsterdam 1006 BE, The Netherlands.
258Department of Human Genetics and Department of Clinical Genetics, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands
BCFR Investigators
Alexander Miron189,190, Miroslav Kapuscinski80, Anita Bane191, Eric Ross192, Saundra S. Buys193 &
Thomas A. Conner194
189Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 190Department of Surgery, Harvard Medical School,
Boston, MA 02215, USA. 191Department of Pathology & Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University,
Hamilton, ON L8V 1C3, Canada. 192Population Studies Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 193Department of Medicine,
Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. 194Huntsman Cancer Institute, Salt Lake City, UT 84112, USA
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications 17
ABCTB Investigators
Rosemary Balleine259, Robert Baxter260, Stephen Braye261, Jane Carpenter262, Jane Dahlstrom263,
John Forbes264, Soon C Lee265, Deborah Marsh260, Adrienne Morey266, Nirmala Pathmanathan267,
Peter Simpson268, Allan Spigelman269, Nicholas Wilcken270 & Desmond Yip271
259Pathology West ICPMR, Westmead, NSW 2145, Australia. 260Kolling Institute of Medical Research, University of Sydney, Royal North Shore
Hospital, Sydney, NSW 2065, Australia. 261Pathology North, John Hunter Hospital, Newcastle, NSW 2305, Australia. 262Australian Breast Cancer
Tissue Bank, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW 2145, Australia. 263Department of Anatomical
Pathology, ACT Pathology, ACT Pathology, Canberra Hospital and ANU Medical School, Australian National University, Canberra, ACT 2605,
Australia. 264Department of Surgical Oncology, Calvary Mater Newcastle Hospital, Australian New Zealand Breast Cancer Trials Group, and School
of Medicine and Public Health, University of Newcastle, Newcastle, NSW 2035, Australia. 265School of Science and Health, The University of
Western Sydney, Sydney, NSW 2650, Australia. 266SydPath St. Vincent’s Hospital, Sydney, NSW 2010, Australia. 267Department of Tissue
Pathology and Diagnostic Oncology, Pathology West, Westmead Breast Cancer Institute, Westmead Hospital, Sydney, NSW 2145, Australia.
268UQ Centre for Clinical Research and School of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia. 269Hereditary Cancer
Clinic, St. Vincent’s Hospital, The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia. 270Crown Princess Mary Cancer Centre, Westmead
Hospital, Sydney, NSW 2145, Australia. 271Department of Medical Oncology, The Canberra Hospital, Canberra, ACT 2605, Australia
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08053-5
18 NATURE COMMUNICATIONS |         (2019) 10:1741 | https://doi.org/10.1038/s41467-018-08053-5 | www.nature.com/naturecommunications
